Start Semaglutide for Weight Loss: Medical Readiness Guide

Q: Do I need any lab work before starting semaglutide?

Yes. Baseline labs should include kidney function (eGFR), liver panel, thyroid function, glucose/HbA1c, lipids, and pancreatic markers. These establish safety clearance and create a comparison baseline for monitoring during treatment.

Q: What is the typical starting dose of semaglutide for weight loss?

Injectable semaglutide typically starts at 0.25 mg weekly, increasing by 0.25 mg every 4 weeks until reaching 1.0–2.4 mg maintenance. Oral semaglutide begins at 3 mg daily, titrating to 7 mg or 14 mg. Your provider tailors the schedule based on your response and tolerance.

Q: How does PlexusDx help with starting semaglutide safely?

PlexusDx offers compounded semaglutide from licensed 503A pharmacies ($149/mo injectable, $209+/month oral) and the Precision Peptide Genetic Test ($99 add-on or $298 standalone) to support baseline genetic insight into peptide pathways, informing provider-guided initiation decisions.

Q: What side effects should I expect when starting semaglutide?

Nausea, vomiting, constipation, and appetite suppression are common early, typically improving within 2–3 weeks. Serious but rare side effects include pancreatitis and severe allergic reactions. Contact your provider immediately for severe or persistent symptoms.

Q: Can genetic testing predict how well semaglutide will work for me?

Genetic variants in GLP1R and related peptide pathway genes reveal predispositions that may provide context for expected response, but do not guarantee exact outcomes. The Precision Peptide Genetic Test should be interpreted with your provider as one component of personalized planning.

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Starting semaglutide for weight loss requires a structured medical approach, not self-initiation. Clinical data shows that baseline metabolic assessment, kidney function evaluation, and thyroid screening should precede therapy, with dosing typically beginning at 0.25 mg weekly and titrating gradually over weeks.

Many patients seeking semaglutide benefit from understanding their individual metabolic context before beginning treatment. Precision-wellness approaches that incorporate biomarker data and genetic factors related to GLP-1 receptor function may help support more targeted provider conversations and personalized dosing strategies.

Medical Eligibility and Pre-Treatment Assessment

Before starting semaglutide, your provider should evaluate kidney function (eGFR), liver health, and BMI status to confirm medical appropriateness. Current guidelines recommend treatment for individuals with BMI ≥30 or BMI ≥27 with weight-related conditions; however, individual medical history determines final eligibility.

Thyroid baseline screening is essential because semaglutide may raise calcitonin levels, requiring careful monitoring in thyroid cancer risk populations. Pregnancy planning, pancreatitis history, and personal or family history of medullary thyroid cancer should be disclosed to your provider before initiating therapy.

Essential Biomarkers and Baseline Testing Before Starting

Comprehensive baseline biomarker profiling supports safer semaglutide initiation and helps establish individual metabolic context. This assessment guides your provider in personalizing dosing, monitoring protocols, and predicting potential response patterns based on your unique physiology.

Biomarker	Why It Matters for Semaglutide Initiation
Fasting Glucose & HbA1c	Establishes baseline glycemic control and predicts metabolic response trajectory
Renal Function (eGFR, Creatinine)	Determines semaglutide safety; dose caution recommended if eGFR <15 mL/min
Liver Function Panel (AST, ALT)	Screens for hepatic impairment that may affect drug metabolism and clearance
Lipid Panel (Total, LDL, HDL, Triglycerides)	Baseline for monitoring metabolic improvements and cardiovascular risk reduction
Thyroid Function (TSH, Free T4)	Establishes thyroid baseline; critical given calcitonin considerations with semaglutide
Pancreatic Markers (Lipase, Amylase)	Rules out pancreatitis history; semaglutide use requires caution in pancreatic disease

Dosing Protocol and Titration Expectations

Semaglutide dosing follows a gradual escalation schedule to minimize gastrointestinal side effects. Standard protocol begins at 0.25 mg subcutaneously weekly, increasing by 0.25 mg every four weeks until reaching maintenance dose of 1.0–2.4 mg weekly, depending on individual tolerance and provider guidance.

Oral semaglutide offers an alternative route with different dosing: typically starting at 3 mg daily, titrating to 7 mg, then potentially 14 mg daily. Your provider will select the formulation and dosing pathway based on your preference, kidney function, and tolerability profile.

Safety Monitoring, Side Effects, and When to Contact Your Provider

Common side effects during initiation include nausea, vomiting, and constipation, typically most pronounced in weeks 1–3. These symptoms often improve as the body adapts; however, persistent severe nausea may warrant dose pause or slower titration under provider supervision.

Serious but rare complications include acute pancreatitis, severe dehydration, and allergic reactions. Contact your provider immediately if you experience abdominal pain, persistent vomiting, jaundice, rapid heartbeat, or signs of allergic reaction. Regular follow-up visits should monitor weight, blood pressure, metabolic labs, and medication tolerance.

Genetic Predispositions in GLP-1 Pathways: What Baseline Testing Reveals

Genetic variants in GLP1R, GIPR, FTO, and MC4R genes influence how your body responds to semaglutide and weight loss interventions. Understanding your genetic predispositions in these peptide pathways may help provide context for expected response patterns and inform provider discussions about treatment strategy.

The Precision Peptide Genetic Test reveals predispositions related to GLP-1 receptor sensitivity, incretin pathways, and appetite-regulation genetics. This information should be interpreted with your provider as context for personalized dosing and monitoring plans, not as a guarantee of medication response or outcome prediction.

How PlexusDx Supports a More Personalized Approach

PlexusDx supports the evidence-based principle that genetic insights into peptide pathways may help provide context for individual semaglutide response potential. Understanding variants in GLP1R, GIPR, FTO, and MC4R can enhance provider conversations about realistic expectations, optimal dosing strategies, and personalized monitoring protocols.

The Precision Peptide Genetic Test (available as a $99 add-on to any PlexusDx product or $298 standalone) identifies predispositions in genes that regulate GLP-1 receptor function and appetite signaling. This test does not predict exact medication response but may support more informed baseline assessment before therapy begins.

When combined with baseline biomarker evaluation and medical assessment, genetic predisposition data from PlexusDx testing can help patients and providers collaboratively refine treatment planning, set realistic weight-loss targets, and establish personalized monitoring intervals that align with individual genetic and metabolic context.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Do I need any lab work before starting semaglutide?